| Year |
Citation |
Score |
| 2015 |
Datta J, Fracol M, McMillan MT, Berk E, Xu S, Goodman N, Lewis DA, DeMichele A, Czerniecki BJ. Association of Depressed Anti-HER2 T-Helper Type 1 Response With Recurrence in Patients With Completely Treated HER2-Positive Breast Cancer: Role for Immune Monitoring. Jama Oncology. 1-5. PMID 26719971 DOI: 10.1001/Jamaoncol.2015.5482 |
0.479 |
|
| 2015 |
Datta J, Rosemblit C, Berk E, Showalter L, Namjoshi P, Mick R, Lee KP, Brod AM, Yang RL, Kelz RR, Fitzpatrick E, Hoyt C, Feldman MD, Zhang PJ, Xu S, et al. Progressive loss of anti-HER2 CD4(+) T-helper type 1 response in breast tumorigenesis and the potential for immune restoration. Oncoimmunology. 4: e1022301. PMID 26451293 DOI: 10.1080/2162402X.2015.1022301 |
0.502 |
|
| 2015 |
Datta J, Berk E, Cintolo JA, Xu S, Roses RE, Czerniecki BJ. Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy. Frontiers in Immunology. 6: 271. PMID 26082780 DOI: 10.3389/Fimmu.2015.00271 |
0.507 |
|
| 2015 |
Datta J, Berk E, Xu S, Fitzpatrick E, Rosemblit C, Lowenfeld L, Goodman N, Lewis DA, Zhang PJ, Fisher C, Roses RE, DeMichele A, Czerniecki BJ. Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer. Breast Cancer Research : Bcr. 17: 71. PMID 25997452 DOI: 10.1186/S13058-015-0584-1 |
0.476 |
|
| 2015 |
Rosemblit C, Datta J, Berk E, Czerniecki BJ. Abstract 1333: CD4 Th1 cytokines and HER-2/HER-3 blockade induces tumor apoptosis in breast cancer Cancer Research. 75: 1333-1333. DOI: 10.1158/1538-7445.Am2015-1333 |
0.567 |
|
| 2015 |
Datta J, Berk E, Xu S, Fitzpatrick E, Lowenfeld L, Goodman N, Lewis D, Roses RE, DeMichele A, Czerniecki BJ. Abstract 1308: Depressed anti-HER2 CD4 Th1 responses correlate with residual disease following neoadjuvant therapy in HER2+ breast cancer patients and can be restored by dendritic cell vaccination Cancer Research. 75: 1308-1308. DOI: 10.1158/1538-7445.Am2015-1308 |
0.504 |
|
| 2014 |
Berk E, Xu S, Czerniecki BJ. Dendritic cells matured in the presence of TLR ligands overcome the immunosuppressive functions of regulatory T cells. Oncoimmunology. 3: e27617. PMID 25101219 DOI: 10.4161/Onci.27617 |
0.547 |
|
| 2014 |
Datta J, Yang RL, Brod AM, Mick R, Berk E, Fitzpatrick E, Xu S, Fox KR, Kelz RR, Czerniecki BJ. Anti-HER2 CD4 T helper type 1 response in breast cancer: Is there a role for immunorestoration? Journal of Clinical Oncology. 32: 636-636. DOI: 10.1200/Jco.2014.32.15_Suppl.636 |
0.461 |
|
| 2014 |
Datta J, Xu S, Terhune JH, Rosemblit C, Berk E, Fitzpatrick E, Czerniecki BJ. Novel strategy to identify MHC class II-promiscuous CD4+ peptides from tumor antigens for utilization in vaccination Journal For Immunotherapy of Cancer. 2: 47. DOI: 10.1186/2051-1426-2-S3-P47 |
0.52 |
|
| 2014 |
Xu S, Cintolo J, Datta J, Rosemblit C, Berk E, Terhune J, Fitzpatrick E, Czerniecki B. Abstract 4079: Reversal of immune evasion mediated by HER2 requires both humoral and cellular HER-2 targeted immune interventions Cancer Research. 74: 4079-4079. DOI: 10.1158/1538-7445.Am2014-4079 |
0.535 |
|
| 2013 |
Terhune J, Berk E, Czerniecki BJ. Dendritic Cell-Induced Th1 and Th17 Cell Differentiation for Cancer Therapy. Vaccines. 1: 527-49. PMID 26344346 DOI: 10.3390/Vaccines1040527 |
0.582 |
|
| 2013 |
Wong JL, Berk E, Edwards RP, Kalinski P. IL-18-primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ T cells to the tumor microenvironment. Cancer Research. 73: 4653-62. PMID 23761327 DOI: 10.1158/0008-5472.Can-12-4366 |
0.657 |
|
| 2013 |
Berk E, Xu S, Xu M, Terhune J, Czerniecki B. Calcium ionophore pre-treatment induces type-1 polarized DCs with enhanced T cell stimulatory function and IL-12 production. Journal For Immunotherapy of Cancer. 1: 199. DOI: 10.1186/2051-1426-1-S1-P199 |
0.575 |
|
| 2012 |
Berk E, Kalinski P. Lymphocyte-polarized DC1s: Effective inducers of tumor-specific CTLs. Oncoimmunology. 1: 1443-1444. PMID 23243623 DOI: 10.4161/Onci.21295 |
0.61 |
|
| 2012 |
Muthuswamy R, Berk E, Junecko BF, Zeh HJ, Zureikat AH, Normolle D, Luong TM, Reinhart TA, Bartlett DL, Kalinski P. NF-κB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells. Cancer Research. 72: 3735-43. PMID 22593190 DOI: 10.1158/0008-5472.CAN-11-4136 |
0.584 |
|
| 2012 |
Berk E, Muthuswamy R, Kalinski P. Lymphocyte-polarized dendritic cells are highly effective in inducing tumor-specific CTLs. Vaccine. 30: 6216-24. PMID 22561311 DOI: 10.1016/J.Vaccine.2012.04.077 |
0.669 |
|
| 2011 |
Berk E, Muthuswamy R. T-cell tolerance induced by non-Treg T-cell-derived TGF-β1. Immunotherapy. 3: 1428. PMID 22200065 |
0.348 |
|
| 2010 |
Watchmaker PB, Berk E, Muthuswamy R, Mailliard RB, Urban JA, Kirkwood JM, Kalinski P. Independent regulation of chemokine responsiveness and cytolytic function versus CD8+ T cell expansion by dendritic cells. Journal of Immunology (Baltimore, Md. : 1950). 184: 591-7. PMID 20018619 DOI: 10.4049/Jimmunol.0902062 |
0.702 |
|
| 2009 |
Kalinski P, Urban J, Narang R, Berk E, Wieckowski E, Muthuswamy R. Dendritic cell-based therapeutic cancer vaccines: What we have and what we need Future Oncology. 5: 379-390. PMID 19374544 DOI: 10.2217/Fon.09.6 |
0.606 |
|
| 2008 |
Watchmaker PB, Urban JA, Berk E, Nakamura Y, Mailliard RB, Watkins SC, van Ham SM, Kalinski P. Memory CD8+ T cells protect dendritic cells from CTL killing. Journal of Immunology (Baltimore, Md. : 1950). 180: 3857-65. PMID 18322193 DOI: 10.4049/Jimmunol.180.6.3857 |
0.654 |
|
| Show low-probability matches. |